397 related articles for article (PubMed ID: 25629315)
1. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Lan B; Hayama E; Kawaguchi N; Furutani Y; Nakanishi T
PLoS One; 2015; 10(1):e0117211. PubMed ID: 25629315
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
3. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
[TBL] [Abstract][Full Text] [Related]
5. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
6. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
Molecules; 2018 May; 23(6):. PubMed ID: 29861433
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.
van Suylen RJ; Smits JF; Daemen MJ
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1423-8. PubMed ID: 9603118
[TBL] [Abstract][Full Text] [Related]
8. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
9. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.
Barman SA; Chen F; Su Y; Dimitropoulou C; Wang Y; Catravas JD; Han W; Orfi L; Szantai-Kis C; Keri G; Szabadkai I; Barabutis N; Rafikova O; Rafikov R; Black SM; Jonigk D; Giannis A; Asmis R; Stepp DW; Ramesh G; Fulton DJ
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1704-15. PubMed ID: 24947524
[TBL] [Abstract][Full Text] [Related]
10. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline.
Yoshihara F; Nishikimi T; Horio T; Yutani C; Takishita S; Matsuo H; Ohe T; Kangawa K
Eur J Pharmacol; 1998 Aug; 355(1):33-9. PubMed ID: 9754936
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
Wang Y; Hu F; Mu X; Wu F; Yang D; Zheng G; Sun X; Gong K; Zhang Z
Biorheology; 2016 Jan; 53(1):13-22. PubMed ID: 26889655
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
[TBL] [Abstract][Full Text] [Related]
15. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.
Deruelle P; Balasubramaniam V; Kunig AM; Seedorf GJ; Markham NE; Abman SH
Biol Neonate; 2006; 90(2):135-44. PubMed ID: 16582538
[TBL] [Abstract][Full Text] [Related]
16. A novel inhibitor of inducible nitric oxide synthase, ONO-1714, does not ameliorate hypoxia-induced pulmonary hypertension in rats.
Jiang BH; Maruyama J; Yokochi A; Mitani Y; Maruyama K
Lung; 2007; 185(5):303-308. PubMed ID: 17721804
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
[TBL] [Abstract][Full Text] [Related]
18. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
20. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
